Related Experiment Video

Updated: Oct 13, 2026

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

[Treatment of severe primary hypercholesterolemia with lovastatin (Mevacor). A new therapeutic principle]

A Leth1, M Munch, B Nielsen

  • 1Københavns Amts Sygehus i Glostrup, lipidambulatoriet, medicinsk afdeling C.

Ugeskrift for Laeger
|November 5, 1990
PubMed

Insights

Lovastatin significantly reduced serum cholesterol and LDL-cholesterol in patients with severe hypercholesterolemia. This cholesterol-lowering drug also increased HDL-cholesterol, with minimal side effects observed.

Area of Science:

  • Cardiology
  • Pharmacology
  • Biochemistry

Background:

  • Severe hypercholesterolemia poses a significant risk for ischemic cardiac disease.
  • Familial hypercholesterolemia is a common genetic form requiring effective treatment.
  • Dietary interventions alone may not be sufficient for managing severe cholesterol levels.

Purpose of the Study:

  • To evaluate the efficacy of lovastatin in reducing serum cholesterol and its subfractions.
  • To assess the impact of lovastatin on lipid profiles in patients with severe hypercholesterolemia.
  • To determine the safety and tolerability of lovastatin treatment.

Main Methods:

  • An open clinical trial involving 59 outpatients with severe hypercholesterolemia.
  • Initial dietary regulation followed by six months of lovastatin treatment (average dose 59 mg/24 hours).
  • Monitoring of serum cholesterol, LDL-cholesterol, HDL-cholesterol, and triglycerides.

Main Results:

  • A 45% decrease in total serum cholesterol and a 44% decrease in LDL-cholesterol were observed.
  • High-density lipoprotein (HDL)-cholesterol increased by over 21%, and triglycerides fell by 20%.
  • The total cholesterol/HDL-cholesterol ratio improved significantly, and side effects were minimal and transient.

Conclusions:

  • Lovastatin demonstrates a pronounced, dosage-related effect in lowering serum cholesterol and LDL-cholesterol.
  • The drug effectively improves the overall lipid profile, including increasing HDL-cholesterol.
  • Lovastatin is well-tolerated in patients with severe hypercholesterolemia, with a favorable safety profile.

More Related Videos

A Familial Hypercholesterolemia Human Liver Chimeric Mouse Model Using Induced Pluripotent Stem Cell-derived Hepatocytes10:56

A Familial Hypercholesterolemia Human Liver Chimeric Mouse Model Using Induced Pluripotent Stem Cell-derived Hepatocytes

Published on: September 15, 2018

LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring08:45

LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring

Published on: November 17, 2018

Related Concept Videos

Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
Treating Helicobacter pylori in Peptic Ulcers: Antimicrobial Therapy01:16

Treating Helicobacter pylori in Peptic Ulcers: Antimicrobial Therapy

Helicobacter pylori, a resilient gram-negative bacterium, can thrive in the stomach's harsh, acidic environment. Infection with H. pylori leads to a cascade of events within the stomach lining. One of the critical disruptions caused by this bacterium is the interference with somatostatin production, a hormone responsible for regulating acid secretion. This interference tips the balance, escalating acid secretion and diminishing bicarbonate levels. This imbalance compromises the defensive...
Cholesterol: Significance and Regulation01:29

Cholesterol: Significance and Regulation

Although not a source of energy, cholesterol plays a significant role as a foundational structure for bile salts, steroid hormones, and vitamin D, as well as being a crucial component of plasma membranes. Approximately 15% of blood cholesterol is derived from our diet, with the remainder synthesized from acetyl CoA by the liver and intestines. Cholesterol is eliminated from the body through its conversion into bile salts, which are eventually discarded in the feces.
Considering cholesterol and...
Lipid Absorption01:24

Lipid Absorption

Dietary triglycerides from chyme in the duodenum are mixed with bile salts produced by the liver to emulsify fats. As a result, large droplets are broken down into smaller ones, increasing the surface area for enzymatic action. Once emulsified, pancreatic lipases hydrolyze the triglycerides into free fatty acids and monoglycerides.
These breakdown products bind with bile salts and lecithin to form micelles, which quickly pass between microvilli to come in close contact with the apical...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...